In previous animal studies, various forms of myostatin inhibition have shown to significantly increase muscle mass in pathophysiologic (i.e., cancer cachexia, Duchenne muscular dystrophy and sarcopenia) and normal mice models [6,15,42]. Here, MSTN is linked to sarcopenia.